Skip to content
Catalyst

PapersPMID:36982259

Beneficial Effect of Cuban Policosanol on Blood Pressure and Serum Lipoproteins Accompanied with Lowered Glycated Hemoglobin and Enhanced High-Density Lipoprotein Functionalities in a Randomized, Placebo-Controlled, and Double-Blinded Trial with Healthy Japanese.

International journal of molecular sciences2023The record ↗

findings
4
compound
1
endpoints
4
no difference found
2
PMID:36982259
  1. Finding, moderate evidencelowersGlycated haemoglobin (HbA1c)
  2. Finding, moderate evidenceraisesHDL cholesterol
  3. Finding, moderate evidenceno difference foundTotal cholesterol (TC)
  4. Finding, moderate evidenceno difference foundTriglycerides
Study, every finding
RCT · 3 months
Dose studied, every finding
20 mg/day (two 10 mg tablets) for 12 weeks
  • “In a group comparison during 12 weeks, the glycated hemoglobin level was 2% lower in the policosanol group than in the placebo group (p = 0.024).”
    Population
    Healthy Japanese adults aged 20 to 65 with normal blood pressure and LDL-C 120-160 mg/dL, advised on calorie, cholesterol, alcohol and exercise limits in both arms
  • Increases HDL cholesterol

    moderatereplicated ×2

    “At week 12, the policosanol group showed a 9.5% higher HDL-C level (p < 0.001) than the placebo group (n = 17).”
    Population
    Healthy Japanese adults aged 20 to 65 with LDL-C 120-160 mg/dL; per-protocol subset excluding participants with low compliance, high-fat diet, heavy drinking or smoking

What did not

  • “Repeated measures ANOVA of TC, TG, LDL-C, and RC levels during the 12 weeks showed no difference between the policosanol group (n = 15) and the placebo group (n = 17) in terms of time and group interaction.”
    • Participants
      32
      Population
      Healthy Japanese adults aged 20 to 65 with LDL-C 120-160 mg/dL; per-protocol subset excluding participants with low compliance, high-fat diet, heavy drinking or smoking
    • Participants
      32
      Population
      Healthy Japanese adults aged 20 to 65 with LDL-C 120-160 mg/dL; per-protocol subset excluding participants with low compliance, high-fat diet, heavy drinking or smoking

Study record

Design
randomised controlled trial
Species
human / mixed
Population
Healthy Japanese adults 20-65 years with LDL-C 120-160 mg/dL and normal blood pressure; Raydel Cuban (sugarcane) policosanol 20 mg/day vs maltodextrin placebo for 12 weeks; lipid analyses in a compliant subset (policosanol n = 15, placebo n = 17). HDL functional assays include zebrafish embryo CML-injection model ex vivo.
Participants
72
Comparator
placebo
Duration
84 days
Endpoints measured
77